Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System

6/10 Late treatment study

Wang et al., medRxiv, doi:10.1101/2020.06.11.20128926 (Preprint)
Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System

Source PDF Share Tweet

Database analysis of 7,592 patients in NYC, showing adjusted HCQ mortality odds ratio OR 0.96, p = 0.82, and HCQ+AZ OR 0.94, p = 0.63

Wang et al., 6/10/2020, retrospective, database analysis, USA, North America, preprint, 3 authors.

risk of death, 5.8% lower, RR 0.94, p = 0.63, treatment 1866, control 5726, odds ratio converted to relative risk.

This study is excluded in meta analysis: confounding by indication is likely and adjustments do not consider COVID-19 severity.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 344 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit